FBR Capital reiterated an Outperform rating and $9.00 price target on Evoke Pharma (NASDAQ: EVOK) following the company's 2Q earnings ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

Noble Financial Keeps Evoke Pharma (EVOK) at 'Hold' Following Q2 Numbers; Still Awaiting Development PlansAugust 16, 2016 8:43 AM Evoke Pharma (EVOK) Tops Q2 EPS by 2cAugust 15, 2016 4:35 PM Evoke Pharma Reports Second Quarter 2016 ResultsAugust 15, 2016 4:31 PM Trading Radar for 8/15: Sysco (SYY), 500.com (WBAI), Famous Dave's (DAVE), Cinedigm (CIDM) ReportAugust 12, 2016 3:17 PM